Roche Announces Global Phase III INShore Study Topline Results on Gazyva for Idiopathic Nephrotic Syndrome in Children and Young Adults
2025-10-30 · Chugai Pharmaceutical · original chugai-pharm.co.jp ↗
Chugai Pharmaceutical Co., Ltd. Nippon Shinyaku Co., Ltd. TOKYO, October 30, 2025 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) and Nippon Shinyaku Co., Ltd. (TOKYO: 4516) announced that Roche issued a news release on October 28th regarding the topline results of the Global Phase III INShore study for idiopathic nephrotic syndrome (INS) in children and young adults (aged 2-25 years). The primary endpoint of sustained complete remission (SCR) at one year (week 52) after treatment initiation showed statistically significant and clinically meaningful improvement in the Gazyva treatment group compared to the mycophenolate mofetil (MMF) group. The safety profile was consistent with the known profile of Gazyva in adults. Please refer to the link below for details of the Roche’s media release: Positive phase III results for Roche’s Gazyva/Gazyvaro in children and young adults with idiopathic nephrotic syndrome https://www.roche.com/media/releases/med-cor-2025-10-28 Trademarks used or mentioned in this release are protected by laws.
The release as fetched from its publisher. chugai-pharm.co.jp ↗